We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+12.09%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$2.04B
AUM Growth
+$139M
Cap. Flow
+$195M
Cap. Flow %
9.6%
Top 10 Hldgs %
52.83%
Holding
78
New
7
Increased
4
Reduced
2
Closed
3

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$101M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$32.1M
3
RVMD icon
Revolution Medicines
RVMD
+$17.2M
4
IOVA icon
Iovance Biotherapeutics
IOVA
+$15.2M
5
ELVN icon
Enliven Therapeutics
ELVN
+$14.5M

Top Sells

Rank Stock Value
1
GERN icon
Geron
GERN
+$19.6M
2
ARVN icon
Arvinas
ARVN
+$5.13M
3
FATE icon
Fate Therapeutics
FATE
+$4.53M
4
THRX
Theseus Pharmaceuticals, Inc. Common Stock
THRX
+$638K
5
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
+$41K

Sector Composition

Rank Sector Weight
1 Healthcare 99.75%
2 Financials 0.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FOLD
26
DELISTED
Amicus Therapeutics
FOLD
$25.8M 1.27%
2,325,000
– –
RCKT icon
27
Rocket Pharmaceuticals
RCKT
$340M
$25.1M 1.23%
1,466,051
– –
AXSM icon
28
Axsome Therapeutics
AXSM
$11.2B
$24.7M 1.21%
400,000
– –
BLU
29
DELISTED
BELLUS Health Inc.
BLU
$23M 1.13%
3,200,000
– –
IOVA icon
30
Iovance Biotherapeutics
IOVA
$1.82B
$22.6M 1.11%
3,705,133
+2,200,000
+146% +$15.2M
EXEL icon
31
Exelixis
EXEL
$13.3B
$22.3M 1.1%
1,150,000
– –
XENE icon
32
Xenon Pharmaceuticals
XENE
$6.06B
$21.5M 1.05%
600,000
– –
ISEE
33
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$20.1M 0.99%
825,000
– –
RAIN
34
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$18.8M 0.92%
2,147,212
– –
PNT
35
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$18.2M 0.89%
2,500,000
– –
RNAM
36
DELISTED
Avidity Biosciences
RNAM
$17.2M 0.85%
1,121,327
– –
DAWN
37
DELISTED
Day One Biopharmaceuticals
DAWN
$15.9M 0.78%
1,189,943
– –
ELVN icon
38
Enliven Therapeutics
ELVN
$3.92B
$15.6M 0.76%
+710,644
New +$14.5M
PMVP icon
39
PMV Pharmaceuticals
PMVP
$59.2M
$15.1M 0.74%
3,163,795
– –
PRTA icon
40
Prothena Corp
PRTA
$425M
$14.5M 0.71%
300,000
– –
KALV
41
DELISTED
KalVista Pharmaceuticals
KALV
$13M 0.64%
+1,650,000
New +$12.3M
CGEM icon
42
Cullinan Oncology
CGEM
$1.01B
$11M 0.54%
1,074,082
– –
NRIX icon
43
Nurix Therapeutics
NRIX
$2.41B
$10.9M 0.53%
1,224,892
– –
ASND icon
44
Ascendis Pharma A/S
ASND
$16B
$10.2M 0.5%
95,000
– –
MORF
45
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$7.53M 0.37%
+200,000
New +$7.37M
ORIC icon
46
Oric Pharmaceuticals
ORIC
$1.15B
$6.01M 0.3%
1,054,000
– –
COGT icon
47
Cogent Biosciences
COGT
$6.65B
$5.67M 0.28%
525,000
– –
RAPT
48
DELISTED
RAPT Therapeutics
RAPT
$5.5M 0.27%
+37,500
New +$7.58M
PANA
49
DELISTED
Panacea Acquisition Corp. II Class A Ordinary Shares
PANA
$5.11M 0.25%
500,000
– –
OBIO icon
50
Orchestra BioMed
OBIO
$238M
$4.89M 0.24%
250,000
– –
1
2
3 4

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q1 2023 Portfolio in Review

As of Q1 2023, Boxer Capital held 78 positions worth $2.04B, up 7.3% from $1.9B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Boxer Capital deployed $195M of net new capital in Q1 2023, opening 7 new positions and adding to 4 existing holdings. Its largest new stake was Sarepta Therapeutics: 775,000 shares worth $107M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Fate Therapeutics, an estimated $4.53M trimmed.

  • Boxer Capital's largest Q1 2023 buy was Sarepta Therapeutics: 775,000 shares worth $107M.
  • Boxer Capital added most to Revolution Medicines in Q1 2023, an estimated $17.2M increase.
  • Boxer Capital's biggest Q1 2023 reduction was Fate Therapeutics, cutting an estimated $4.53M.
  • Boxer Capital fully exited Geron in Q1 2023, selling an estimated $19.6M.
  • Boxer Capital's ten largest holdings make up 53% of its $2.04B portfolio in Q1 2023.
  • Boxer Capital opened 7 new positions and closed 3 in Q1 2023.
  • Boxer Capital's portfolio value rose 7.3% quarter-over-quarter to $2.04B.

Based on Boxer Capital's 13F filing for Q1 2023, filed 15 May 2023.